Hims & Hers Health (HIMS) on Solana

HIMS shares fell 4% to close at $28.44 to open September, weighed down by a new FDA alert warning consumers about unapproved compounded GLP-1 drugs. The agency cited 990 adverse-event reports involving compounded semaglutide and over 730 involving compounded tirzepatide as of May 31, flagging dosing errors requiring hospitalization, contamination risks, and fraudulent labeling — and announced an import "green list" to tighten control of GLP-1 ingredient supply chains. The news reinforces pressure on Hims, which had already pivoted away from its own compounded semaglutide offering under a March agreement with Novo Nordisk to focus on FDA-approved Ozempic and Wegovy, a shift that pushed Q2 gross margins down to roughly 64% from 76% a year earlier.

The headwinds overshadowed a genuine positive: Hims officially launched in Australia by rebranding its Eucalyptus-acquired Pilot platform, extending care coverage to round-the-clock availability across sexual health, weight loss, and hair loss services. The company reported Q2 revenue of $753 million and reaffirmed 2026 full-year guidance of $3.1–$3.3 billion, though a net loss of $86 million — including restructuring and legal costs — kept investor sentiment cautious heading into the new month.

Following a 14.6% share price decline, Hims & Hers Health (HIMS) is drawing renewed attention as a potential value play on revenue metrics. The stock currently trades at a price-to-sales ratio of 2.6x — above the healthcare sector average of 1.4x but in line with its peer group at 2.3x — while a fundamentals-based model from Simply Wall St suggests fair value closer to 5.1x P/S, implying the stock trades at a meaningful discount to intrinsic worth on that measure.

Broader quality checks tell a more mixed story, with HIMS scoring 3 out of 6 on a composite valuation scorecard. Bull-case analysts cite an 83% upside based on demand for the company's expanding product lines — including peptide therapies, Hims TRT, Hers Menopause, and a GRAIL stake — while bears argue a 25% overvaluation is justified given regulatory scrutiny around billing and privacy practices, an FTC payment dispute with Visa, and intensifying competition in the telehealth sector. Investors are left weighing whether the post-drop P/S discount adequately compensates for those headwinds.

Hims & Hers Health fell 14.6% even as the company posted quarterly revenue of $753.2 million — up 38.2% year-over-year — and raised both its next-quarter revenue guidance and full-year EBITDA outlook above analyst expectations, adding 307,000 customers to reach 2.89 million total. The counterintuitive sell-off reflects investor concern that mounting legal and regulatory exposure is eroding the growth story faster than the financials suggest.

The company faces an FTC lawsuit alongside class-action claims centered on alleged privacy violations and billing irregularities, risks that cut directly at its subscription-driven, data-sensitive business model. Visa is also monitoring dispute activity tied to billing practices, a flag that could constrain customer growth and compress margins if it escalates. Analysts noted the market is now weighing whether the compliance costs, reputational drag, and management distraction from these issues will undercut the operational momentum that has driven HIMS's expansion — a concern that, for now, appears to be outweighing the upbeat guidance.

Hims & Hers Health shares fell 8% on Monday — their steepest single-day decline in nearly a month — after Visa placed the company in its Acquirer Monitoring Program following a surge in credit card disputes in July. Weight-loss memberships were the primary driver, accounting for 75% of the company's credit card disputes. To exit the program, Hims must keep its dispute rate below 1.5% of transactions for three consecutive months, and the company faces an estimated $75,000 penalty in September from $8-per-dispute surcharges. The pricing structure on weight-loss subscriptions — $39 for the first month rising to $149 with automatic renewal — has drawn scrutiny as a likely factor behind the elevated dispute rate.

Despite the selloff, Truist struck a cautiously constructive tone, raising its price target on HIMS to $32 from $27 while maintaining a Hold rating. Truist's proprietary card data showed stronger-than-expected retention among existing compounded GLP-1 customers, suggesting users are staying on their subscriptions even amid billing friction. The firm also noted that deferred compounded GLP-1 revenue provided a meaningful boost to recent quarterly results, pointing to underlying demand that the payment dispute headline may obscure.

Hims & Hers Health reported Q2 revenue of $753.2 million, up 38% year-over-year and well ahead of the $699 million analyst consensus, with subscriber count growing 19% to 2.89 million and monthly revenue per subscriber rising 21% to $92. Despite the top-line beat, shares fell over 2% as the company swung to a $127.9 million net loss from a $43.5 million profit in the same quarter a year earlier — far worse than the 5-cent-per-share loss analysts had modeled.

The market's concern centers on gross margin, which declined for the fourth consecutive quarter as the company accelerated investment in branded GLP-1 weight-loss drugs and international expansion. CFO Yemi Okupe acknowledged that margins are likely to remain below historical levels going forward. Management raised full-year revenue guidance to $3.1–$3.3 billion and reaffirmed a 2030 revenue target of at least $6.5 billion, but the combination of deepening losses and an FTC lawsuit over alleged user data misuse kept investor enthusiasm in check.

The Q2 2026 earnings call for Hims & Hers Health surfaced several strategic priorities through analyst questioning. Canaccord's Maria Ripps pressed management on the Novo Nordisk partnership, with the company disclosing that "immersive experiences" tied to the collaboration are already reducing cancellation rates in weight loss offerings — a signal of improving customer retention. Needham's Ryan MacDonald asked about integrating the Eucalyptus acquisition into international markets, and CEO Andrew Dudum pointed to regulatory opportunities in peptides and longevity therapies abroad as a key growth vector. Morgan Stanley's Craig Hettenbach drew out the company's AI rollout sequence: the Hers weight loss line received initial AI feature deployment due to its complexity, with Hims offerings following in subsequent phases.

On subscriber growth sustainability, Nephron Research's Eric Percher questioned whether the rapid pace could continue; management attributed momentum to new weight loss therapies and re-acceleration in core categories, with Eucalyptus described as a secondary contributor to domestic results. Barclays' Glen Santangelo pressed CFO Okupe on Eucalyptus margin impact and long-term guidance, receiving confirmation that the acquisition operates at or near breakeven, with free cash flow and EBITDA generation cited as the framework for evaluating the deal against ongoing growth investments.

Hims & Hers Health (HIMS) currently trades at a price-to-sales ratio of roughly 2.8x, below the peer average of 4.0x and well under a fair-value model estimate of 5.4x, according to a Yahoo Finance analysis. The stock scores four out of six on a structured valuation checklist, reflecting a mixed rather than clearly cheap picture. HIMS is down about 36% over the past year despite a roughly 341% five-year return, with the gap partly attributed to an ongoing FTC lawsuit that analysts say weighs on margin expectations and investor sentiment.

The bull case in the analysis points to 82% potential undervaluation, citing demand for new product lines including Hims TRT, Hers Menopause, and a Labs offering, along with the AI-driven Hers app and acquisitions such as YourBio, Livewell, and a GRAIL stake. The bear case projects only 7% overvaluation risk, but flags regulatory and operational exposure as limits on near-term profitability. The FTC's lawsuit over alleged privacy violations and deceptive billing practices remains the central legal overhang the market is pricing in.

Hims & Hers Health posted Q2 2026 revenue of $753 million, a 40% year-over-year increase, while adding 300,000 net new subscribers to bring its total base to nearly 3 million. Adjusted EBITDA came in at $60 million (8% margin), with a GAAP net loss of $86 million that was largely driven by $81 million in non-recurring costs. Gross margin was 64%, down roughly 6 points quarter-over-quarter. International revenue reached $131 million — 17x the prior-year figure — reflecting the contribution of the Eucalyptus acquisition, with the UK, Australia, and Germany each running above $100 million on an annualized basis.

On the back of the beat, management raised full-year 2026 guidance to $3.1–$3.3 billion in revenue and $275–$325 million in adjusted EBITDA, while guiding Q3 to $880–$900 million in revenue. CEO Andrew Dudum highlighted rapid AI adoption within the care platform, noting customers are engaging three times more frequently and that AI now handles 80% of patient questions, cutting non-clinical tasks in half. The testosterone specialty is approaching a $100 million annual revenue run rate, and peptide products remain in the pipeline pending final FDA rulemaking. A Novo Nordisk collaboration continues to support Wegovy pill distribution and market expansion.

Hims & Hers Health pushed back sharply against the Federal Trade Commission's lawsuit, calling the agency's claims "baseless" and accusing regulators of contorting the law "to try to manufacture claims." The telehealth company denied all allegations and said the FTC disregarded evidence the company had submitted over the course of a three-year investigation into its conduct.

The FTC's suit alleges Hims & Hers used pixel trackers from Meta, Snap, Microsoft, Pinterest, Reddit, and X to share patients' sensitive health data with advertisers without adequate consent — a practice the company disputes. Hims & Hers pointed to its Privacy Policy, which it says gives customers clear control over how their data is used and specifies that information shared with healthcare providers is used solely for care. The agency also alleged deceptive billing, including charging patients before they had consulted with a provider and making subscriptions difficult to cancel, charges the company also denies.

Hims & Hers Health is on track for a fourth consecutive weekly loss — down roughly 4% for the week and 59% over the past year — as Morningstar maintains its "no moat" rating and assigns the stock a "very high" uncertainty designation. The firm sets a fair value of $23, implying approximately 15% further downside from current levels, citing an absence of structural competitive advantages sufficient to generate excess returns and a business model that remains highly sensitive to regulatory and legal headlines.

The FTC lawsuit filed this week — alleging deceptive subscription practices and the sharing of sensitive health data with Meta and Snap, on which Hims had already disclosed roughly $15 million in probable losses — compounds that uncertainty, with Morningstar warning a settlement could prove costlier than prior estimates. The analyst gap is also significant: management targets $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, while Morningstar projects $4.3 billion and roughly $720 million respectively, reflecting skepticism about the pace of subscriber growth and the execution risk around the company's peptide compounding initiative, where an FDA advisory committee backed six of seven compounds but formal approval of those recommendations has not yet occurred.